These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23553733)

  • 21. Rapid virological response: is it four or eight weeks?
    Milazzo L; Foschi A; Antinori S
    Hepatology; 2012 Mar; 55(3):979; author reply 980-1. PubMed ID: 22161760
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of microarray analysis for predicting treatment responsiveness in patients with chronic hepatitis C viral infection.
    Kim IJ; Kang HC; Park JG
    Gastroenterology; 2005 Nov; 129(5):1803; author reply 1803-4. PubMed ID: 16285984
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.
    Petta S; Grimaudo S; Marco VD; Scazzone C; Macaluso FS; Cammà C; Cabibi D; Pipitone R; Craxì A
    J Viral Hepat; 2013 Jul; 20(7):486-93. PubMed ID: 23730842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why is the sustained virological response rate among HCV genotype 3 infected patients in Pakistan low?
    Qureshi S; Shafiei-Guilani M; Aalaei-Andabili SH
    J Coll Physicians Surg Pak; 2012 Jan; 22(1):70-1; author reply 71. PubMed ID: 22237201
    [No Abstract]   [Full Text] [Related]  

  • 25. [Targeted against every genotype].
    Urban & Vogel
    MMW Fortschr Med; 2015 Apr; 157(6):34. PubMed ID: 26015198
    [No Abstract]   [Full Text] [Related]  

  • 26. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 27. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variations in heme oxygenase-1 and chronic hepatitis.
    Bonkovsky HL; Lambrecht RW; Naishadham D
    Hepatology; 2010 Jul; 52(1):400-1. PubMed ID: 20232486
    [No Abstract]   [Full Text] [Related]  

  • 29. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis.
    García-Álvarez M; Pineda-Tenor D; Jiménez-Sousa MA; Fernández-Rodríguez A; Guzmán-Fulgencio M; Resino S
    Hepatology; 2014 Nov; 60(5):1541-50. PubMed ID: 24975775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to: 'Evidence recommending antiviral therapy in hepatitis C'.
    van der Meer AJ; Feld JJ; Zeuzem S; Janssen HL
    J Hepatol; 2014 May; 60(5):1102-3. PubMed ID: 24445220
    [No Abstract]   [Full Text] [Related]  

  • 31. [An update on the management of chronic hepatitis C].
    Bihl F; Pache I; Hess J; Moradpour D
    Rev Med Suisse; 2010 Jan; 6(233):174, 176-9. PubMed ID: 20214188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.
    Fernández-Rodríguez A; Jiménez-Sousa MÁ; Resino S
    Gene; 2013 Jun; 522(1):121. PubMed ID: 23506831
    [No Abstract]   [Full Text] [Related]  

  • 33. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues.
    Yu ML; Dai CY; Huang JF; Hsieh MY; Chuang WL
    Hepatology; 2008 May; 47(5):1792-3; author reply 1793-4. PubMed ID: 18435463
    [No Abstract]   [Full Text] [Related]  

  • 34. Has genetics eradicated the good old predictors of hepatitis C treatment response?
    Pawlotsky JM
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):157-8. PubMed ID: 21492738
    [No Abstract]   [Full Text] [Related]  

  • 35. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Association of Vitamin D Receptor Polymorphisms with Response to Antiviral Therapy in Patients with Chronic Hepatitis C].
    Wang C; Wu Q; Wei XT; Li ZZ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 47(2):227-31. PubMed ID: 27263300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatitis C in 2007...progress and challenges].
    Marcellin P
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S3-6. PubMed ID: 17965628
    [No Abstract]   [Full Text] [Related]  

  • 38. No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.
    Bonkovsky HL; Salek J
    Gastroenterology; 2005 Oct; 129(4):1361-2. PubMed ID: 16230097
    [No Abstract]   [Full Text] [Related]  

  • 39. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to Messori.
    Rein DB
    Clin Infect Dis; 2015 Dec; 61(12):1892-3. PubMed ID: 26261202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.